Strata Critical Medical, Inc. (SRTA)

Strata Critical Medical, Inc. (NASDAQ: SRTA) is a healthcare services company that moves organs, transplant teams, and patients at time-critical speed, and provides specialized clinical services like perfusion and organ preservation to support transplantation and cardiac surgery. The company was formerly known as Blade Air Mobility, Inc., a venture-backed air taxi startup, until Blade’s medical division was spun out and rebranded as Strata in August 2025. The new Strata focuses exclusively on aviation-based medical logistics and clinical services — a vertical that had become the strongest part of the parent company.

Two businesses, one clock

Strata operates two related but distinct businesses: Logistics and Clinical. The Logistics division moves human organs and transplant teams by air and ground transportation. Time is the entire constraint. A donated organ becomes less viable the longer it sits outside a body — a heart typically remains viable for four to six hours, a liver about eight to twelve hours, kidneys as long as twenty-four to forty-eight hours depending on preservation method. Every minute counts. Strata operates helicopters and operates ground teams in coordination with transplant centers to move organs from donors to recipients with minimal delay. The company also manages the placement logistics — connecting available organs with waiting recipients and coordinating the movements of multiple teams and facilities.

The Clinical division provides specialized medical staff and services at transplant centers and major hospitals. Organ recovery requires surgeons trained in procurement, teams that know how to preserve organs while they are in transit, and post-transplant support. Strata employs perfusionists — specialists who manage the machines and fluids that keep organs alive outside the body — and surgeons, nurses, and technicians trained in organ recovery, normothermic regional perfusion (a newer preservation technique), and extracorporeal membrane oxygenation (ECMO). The company also provides cardiac perfusion services, blood management and autotransfusion services, and equipment rentals for these specialized procedures.

These two businesses are joined at the hip. Logistics without clinical expertise is just transport; clinical expertise without reliable logistics is isolated to a few centers. Strata offers the full chain, which means hospitals can contract with one vendor for both the transport and the specialized clinical teams.

How Strata makes money

Revenue flows from transplant centers and hospitals paying for organ recovery services, organ transport, and clinical staffing. The Logistics division charges for aviation services — typically per flight hour — and for ground transport coordination. The Clinical division charges per procedure or per staffing day. Both streams depend on absolute volume: the more organs recovered, the more flights, the more clinical cases. The United States performs roughly 40,000 organ transplants per year, and Strata’s services touch a significant portion of those cases.

The company serves a small and concentrated customer base. Strata’s clients are transplant centers, organ procurement organizations, and major teaching hospitals — roughly a few hundred facilities nationwide. Customer concentration is high, which means large contracts matter enormously to the top line. Losing a major hospital or transplant network would be a material event. On the flip side, the network effects are strong: a hospital that trusts Strata with organ recovery is likely to use Strata for other services like perfusion staffing or ECMO support, expanding the relationship over time.

Geography and operational complexity

The United States is Strata’s only market. Organ transplantation and procurement are heavily regulated by the federal government, managed through United Network for Organ Sharing (UNOS), and coordinate across hospital networks. A company cannot operate organ logistics without integration into this network. Strata’s footprint is strongest on the coasts — particularly in the Northeast and California, where there are high transplant volumes and dense hospital concentrations — but the company has been expanding inland.

The geographical dispersion of donors and recipients is a core operational challenge. Strata maintains hubs and bases in multiple cities to minimize transport time. Aviation weather, airport access, and ground logistics at dozens of hospitals add layers of complexity. A hospital in Denver faces different transport constraints than a center in Miami. Strata must manage this complexity reliably and at speed, because a missed organ or a delayed recovery can cost a patient’s life.

Risks and competitive dynamics

The market for organ recovery services is not crowded. Few companies have the combination of aviation assets, transplant expertise, and regulatory relationships to operate across state lines and hospital networks. This is a moat born of specialization and regulatory complexity rather than brand or scale. But the moat is not impenetrable. Larger healthcare companies or consolidators could decide the market is worth entering, or they could acquire Strata. Insurance companies and hospital networks might begin to demand exclusive contracts or push procurement back in-house.

The bigger risk is regulatory and operational. Any incident involving organ loss, patient harm, or breach of UNOS protocols could be catastrophic for the company’s reputation and certifications. The company is also labor-intensive: it must employ trained perfusionists, surgeons, and pilots, and these are specialized professionals in tight supply. Turnover or inability to hire and retain staff would directly harm the company’s ability to fulfill contracts.

Volume depends on organ donation rates, which are determined by public policy and demographic trends. Newer preservation technologies like normothermic regional perfusion expand the window for organ viability and could increase transplant volumes, which would benefit Strata. Conversely, if organ donation rates fall, Strata’s revenue falls too.

The path to profitability

Strata was spun out from Blade Air Mobility in 2025. The medical division had been the stable, profitable part of Blade while the air-taxi business consumed capital. Early reports suggest the medical division has been growing revenue at a high rate — over 80 percent in the first quarter of 2026 — and is approaching cash-flow breakeven or profitability. The company appears to be at a size and maturity where it can sustain operations from revenue rather than venture funding.

For investors studying Strata, track quarterly revenue growth, particularly in the Clinical division, which carries higher margins than Logistics. Watch for any material loss of customer contracts or labor challenges. Monitor whether the company is able to continue expanding its aviation network and geographical footprint. The business is small, specialized, and has a clear moat, but it is also dependent on a single market and a small number of large customers. The annual 10-K (SEC CIK 0001779128) will reveal the full customer list and contract terms.